title: [Erythropoietin level in the blood of patients with diabetes mellitus type 2].
abstract: 52 patients with diabetes mellitus type II (23 of them were treated by diabetic diet, 12 were on oral antidiabetic drugs and 17 were treated by insulin), and in 31 healthy subjects the serum concentrations of erythropoietin (EPO), ferritin, iron, TIBC and hematocrit value, haemoglobin concentration and erythrocytes were measured. In diabetic patients higher but in insulin treated patients significantly higher plasma erythropoietin concentrations were found than in healthy subjects. In diabetic patients the physiological negative correlation between plasma erythropoietin concentration, haematocrit value, haemoglobin concentration and erythrocytes respectively was absent. In diabetic patients plasma ferritin concentrations were significantly higher than in normals.
  
  
  CONCLUSIONS
  patients with diabetes mellitus type II are characterized by elevated plasma erythropoietin and ferritin concentrations and dissociation of the physiological feedback between plasma erythropoietin and intensity of erythropoiesis.
authors.affiliation: Katedry i Kliniki Nefrologii Sl. AM w Katowicach.
authors.forename: W
authors.initials: W
authors.lastname: Grzeszczak
authors.forename: E
authors.initials: E
authors.lastname: Franek
authors.forename: F
authors.initials: F
authors.lastname: Kokot
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000628:therapy; D003927:Diet, Diabetic; D004906:Erythrocyte Count / Q000187:drug effects; D004921:Erythropoietin / Q000097:blood*; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008875:Middle Aged; D012016:Reference Values
chemical_list: D006454:Hemoglobins; D007004:Hypoglycemic Agents; D007328:Insulin; D004921:Erythropoietin; D005293:Ferritins
vernacular_title: Stezenie erytropoetyny we krwi chorych na cukrzyce typu II.